Advertisement

Chemotherapy Resistance in Lung Cancer

  • Eric S. KimEmail author
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 893)

Abstract

Despite a growing interest in development of non-cytotoxic targeted agents, systemic chemotherapy is still the mainstay of treatment for both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). However, chemotherapy resistance limits our ability to effectively treat advanced lung cancer. Some lung tumors are intrinsically resistant to chemotherapy, and in virtually all cases, even the initial responders rapidly develop acquired resistance. While targeting histology could result in enhanced tumor sensitivity to a particular chemotherapeutic agent, better understanding of molecular determinants of chemotherapy sensitivity/resistance would be critically important. Development of predictive biomarkers to personalize chemotherapeutic agents and combining novel agents targeting specific resistance pathways with standard chemotherapy could be some promising strategies to overcome chemotherapy resistance in lung cancer. In this chapter, we will discuss some key mechanisms of resistance for commonly used chemotherapeutic agents in lung cancer.

Keywords

Chemotherapy resistance Drug resistance Lung cancer Non-small cell lung cancer Small cell lung cancer Multidrug resistance 

References

  1. 1.
    Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ (2008) Medical treatment of advanced testicular cancer. JAMA 299(6):672–684. doi: 10.1001/jama.299.6.672 PubMedCrossRefGoogle Scholar
  2. 2.
    Gately DP, Howell SB (1993) Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 67(6):1171–1176PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Andrews PA, Howell SB (1990) Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 2(2):35–43PubMedGoogle Scholar
  4. 4.
    Shellard SA, Fichtinger-Schepman AM, Lazo JS, Hill BT (1993) Evidence of differential cisplatin-DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines. Anticancer Drugs 4(4):491–500PubMedCrossRefGoogle Scholar
  5. 5.
    Kawai H, Kiura K, Tabata M, Yoshino T, Takata I, Hiraki A, Chikamori K, Ueoka H, Tanimoto M, Harada M (2002) Characterization of non-small-cell lung cancer cell lines established before and after chemotherapy. Lung Cancer 35(3):305–314, S0169500201004305 [pii]PubMedCrossRefGoogle Scholar
  6. 6.
    Bungo M, Fujiwara Y, Kasahara K, Nakagawa K, Ohe Y, Sasaki Y, Irino S, Saijo N (1990) Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum(II) in human non-small cell lung cancer cell lines: relation to DNA damage and repair. Cancer Res 50(9):2549–2553PubMedGoogle Scholar
  7. 7.
    Kim ES, Lee JJ, He G, Chow CW, Fujimoto J, Kalhor N, Swisher SG, Wistuba II, Stewart DJ, Siddik ZH (2012) Tissue platinum concentration and tumor response in non-small-cell lung cancer. J Clin Oncol 30(27):3345–3352. doi: 10.1200/JCO.2011.40.8120 PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Ishida S, Lee J, Thiele DJ, Herskowitz I (2002) Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A 99(22):14298–14302. doi: 10.1073/pnas.162491399162491399 [pii]PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Song IS, Savaraj N, Siddik ZH, Liu P, Wei Y, Wu CJ, Kuo MT (2004) Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther 3(12):1543–1549, 3/12/1543 [pii]PubMedGoogle Scholar
  10. 10.
    Chen HH, Yan JJ, Chen WC, Kuo MT, Lai YH, Lai WW, Liu HS, Su WC (2012) Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy. Lung Cancer 75(2):228–234. doi: 10.1016/j.lungcan.2011.06.011 PubMedCrossRefGoogle Scholar
  11. 11.
    Ishida S, McCormick F, Smith-McCune K, Hanahan D (2010) Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell 17(6):574–583. doi: 10.1016/j.ccr.2010.04.011, S1535-6108(10)00150-9 [pii]PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Stewart DJ, Issa JP, Kurzrock R, Nunez MI, Jelinek J, Hong D, Oki Y, Guo Z, Gupta S, Wistuba II (2009) Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res 15(11):3881–3888. doi: 10.1158/1078-0432.CCR-08-2196 PubMedCrossRefGoogle Scholar
  13. 13.
    Bando T, Fujimura M, Kasahara K, Ueno T, Matsuda T (2000) Selective beta2-adrenoceptor agonist enhances sensitivity to cisplatin in non-small cell lung cancer cell line. Oncol Rep 7(1):49–52PubMedGoogle Scholar
  14. 14.
    Bando T, Fujimura M, Kasahara K, Matsuda T (1998) Significance of Na+, K(+)-ATPase on intracellular accumulation of cis-diamminedichloroplatinum(II) in human non-small-cell but not in small-cell lung cancer cell lines. Anticancer Res 18(2A):1085–1089PubMedGoogle Scholar
  15. 15.
    Bando T, Fujimura M, Kasahara K, Matsuda T (1998) Role of thromboxane receptor on the intracellular accumulation of cis-diamminedichloroplatinum(II) in non-small-cell but not in small-cell lung cancer cell lines. Anticancer Res 18(2A):1079–1084PubMedGoogle Scholar
  16. 16.
    Fujimura M, Kasahara K, Shirasaki H, Heki U, Iwasa K, Ueda A, Matsuda T (1999) Up-regulation of ICH-1L protein by thromboxane A2 antagonists enhances cisplatin-induced apoptosis in non-small-cell lung-cancer cell lines. J Cancer Res Clin Oncol 125(7):389–394PubMedCrossRefGoogle Scholar
  17. 17.
    Bando T, Fujimura M, Kasahara K, Shibata K, Shirasaki H, Heki U, Iwasa K, Ueda A, Tomikawa S, Matsuda T (1997) Exposure to sorbitol induces resistance to cisplatin in human non-small-cell lung cancer cell lines. Anticancer Res 17(5A):3345–3348PubMedGoogle Scholar
  18. 18.
    Tokuchi Y, Isobe H, Takekawa H, Hanada T, Ishida T, Ogura S, Itoh K, Furudate M, Saito K, Kawakami Y (1998) Predicting chemotherapeutic response to small-cell lung cancer of platinum compounds by thallium-201 single-photon emission computerized tomography. Br J Cancer 77(8):1363–1368PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Yamamoto Y, Nishiyama Y, Satoh K, Takashima H, Ohkawa M, Fujita J, Kishi T, Matsuno S, Tanabe M (1998) Comparative study of technetium-99m-sestamibi and thallium-201 SPECT in predicting chemotherapeutic response in small cell lung cancer. J Nucl Med 39(9):1626–1629PubMedGoogle Scholar
  20. 20.
    Nakagawa T, Inoue Y, Kodama H, Yamazaki H, Kawai K, Suemizu H, Masuda R, Iwazaki M, Yamada S, Ueyama Y, Inoue H, Nakamura M (2008) Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) correlates with cisplatin resistance in human non-small cell lung cancer xenografts. Oncol Rep 20(2):265–270PubMedGoogle Scholar
  21. 21.
    Yoh K, Ishii G, Yokose T, Minegishi Y, Tsuta K, Goto K, Nishiwaki Y, Kodama T, Suga M, Ochiai A (2004) Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res 10(5):1691–1697PubMedCrossRefGoogle Scholar
  22. 22.
    Ota S, Ishii G, Goto K, Kubota K, Kim YH, Kojika M, Murata Y, Yamazaki M, Nishiwaki Y, Eguchi K, Ochiai A (2009) Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer 64(1):98–104PubMedCrossRefGoogle Scholar
  23. 23.
    Hu Y, Lin DM, Cheng SJ, Liu YN, Feng FY (2006) Influences of PC cell-derived growth factor and breast cancer resistance protein on the curative effects of platinum-based chemotherapeutic regimens for advanced non-small cell lung cancer. Zhonghua Yi Xue Za Zhi 86(37):2611–2614PubMedGoogle Scholar
  24. 24.
    Hu Y, Feng FY, Cheng SJ, Gao YN, Xiao T, Liu YN (2006) Expression of serum breast drug-resistance protein in predicting chemosensitivity of NSCLC. Zhonghua Zhong Liu Za Zhi 28(10):750–752PubMedGoogle Scholar
  25. 25.
    Meijer C, Mulder NH, Hospers GA, Uges DR, de Vries EG (1990) The role of glutathione in resistance to cisplatin in a human small cell lung cancer cell line. Br J Cancer 62(1):72–77PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Jain N, Lam YM, Pym J, Campling BG (1996) Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin. Cancer 77(9):1797–1808PubMedCrossRefGoogle Scholar
  27. 27.
    Hospers GA, Meijer C, de Leij L, Uges DR, Mulder NH, de Vries EG (1990) A study of human small-cell lung carcinoma (hSCLC) cell lines with different sensitivities to detect relevant mechanisms of cisplatin (CDDP) resistance. Int J Cancer 46(1):138–144PubMedCrossRefGoogle Scholar
  28. 28.
    Moritaka T, Kiura K, Ueoka H, Tabata M, Segawa Y, Shibayama T, Takigawa N, Ohnoshi T, Harada M (1998) Cisplatin-resistant human small cell lung cancer cell line shows collateral sensitivity to vinca alkaloids. Anticancer Res 18(2A):927–933PubMedGoogle Scholar
  29. 29.
    Fokkema E, Groen HJ, Helder MN, de Vries EG, Meijer C (2002) JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin. Biochem Pharmacol 63(11):1989–1996PubMedCrossRefGoogle Scholar
  30. 30.
    Oshita F, Fujiwara Y, Saijo N (1992) Radiation sensitivities in various anticancer-drug-resistant human lung cancer cell lines and mechanism of radiation cross-resistance in a cisplatin-resistant cell line. J Cancer Res Clin Oncol 119(1):28–34PubMedCrossRefGoogle Scholar
  31. 31.
    Meijer C, Mulder NH, Timmer-Bosscha H, Sluiter WJ, Meersma GJ, de Vries EG (1992) Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res 52(24):6885–6889PubMedGoogle Scholar
  32. 32.
    Kurokawa H, Ishida T, Nishio K, Arioka H, Sata M, Fukumoto H, Miura M, Saijo N (1995) Gamma-glutamylcysteine synthetase gene overexpression results in increased activity of the ATP-dependent glutathione S-conjugate export pump and cisplatin resistance. Biochem Biophys Res Commun 216(1):258–264PubMedCrossRefGoogle Scholar
  33. 33.
    Zhan M, Liu X (1999) Schedule-dependent reversion of cisplatin resistance by 5-fluorouracil in a cisplatin-resistant human lung adenocarcinoma cell line A549DDP. Chin Med J (Engl) 112(4):336–339Google Scholar
  34. 34.
    Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22(47):7265–7279. doi: 10.1038/sj.onc.1206933 PubMedCrossRefGoogle Scholar
  35. 35.
    van de Vaart PJ, Belderbos J, de Jong D, Sneeuw KC, Majoor D, Bartelink H, Begg AC (2000) DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer 89(2):160–166PubMedCrossRefGoogle Scholar
  36. 36.
    Takenaka T, Yoshino I, Kouso H, Ohba T, Yohena T, Osoegawa A, Shoji F, Maehara Y (2007) Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer. Int J Cancer 121(4):895–900. doi: 10.1002/ijc.22738 PubMedCrossRefGoogle Scholar
  37. 37.
    Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC, IB Investigators (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355(10):983–991. doi: 10.1056/NEJMoa060570 PubMedCrossRefGoogle Scholar
  38. 38.
    Booton R, Ward T, Ashcroft L, Morris J, Heighway J, Thatcher N (2007) ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Thorac Oncol 2(10):902–906. doi: 10.1097/JTO.0b013e318155a637 PubMedCrossRefGoogle Scholar
  39. 39.
    Friboulet L, Olaussen KA, Pignon JP, Shepherd FA, Tsao MS, Graziano S, Kratzke R, Douillard JY, Seymour L, Pirker R, Filipits M, Andre F, Solary E, Ponsonnailles F, Robin A, Stoclin A, Dorvault N, Commo F, Adam J, Vanhecke E, Saulnier P, Thomale J, Le Chevalier T, Dunant A, Rousseau V, Le Teuff G, Brambilla E, Soria JC (2013) ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med 368(12):1101–1110. doi: 10.1056/NEJMoa1214271 PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Bepler G, Williams C, Schell MJ, Chen W, Zheng Z, Simon G, Gadgeel S, Zhao X, Schreiber F, Brahmer J, Chiappori A, Tanvetyanon T, Pinder-Schenck M, Gray J, Haura E, Antonia S, Fischer JR (2013) Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. doi: 10.1200/JCO.2012.46.9783 PubMedPubMedCentralGoogle Scholar
  41. 41.
    Kasahara K, Fujiwara Y, Nishio K, Ohmori T, Sugimoto Y, Komiya K, Matsuda T, Saijo N (1991) Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res 51(12):3237–3242PubMedGoogle Scholar
  42. 42.
    Joseph MG, Banerjee D, Kocha W, Feld R, Stitt LW, Cherian MG (2001) Metallothionein expression in patients with small cell carcinoma of the lung: correlation with other molecular markers and clinical outcome. Cancer 92(4):836–842PubMedCrossRefGoogle Scholar
  43. 43.
    Goodsell DS (2000) The molecular perspective: microtubules and the taxanes. Oncologist 5(4):345–346PubMedCrossRefGoogle Scholar
  44. 44.
    Verdier-Pinard P, Wang F, Martello L, Burd B, Orr GA, Horwitz SB (2003) Analysis of tubulin isotypes and mutations from taxol-resistant cells by combined isoelectrofocusing and mass spectrometry. Biochemistry 42(18):5349–5357PubMedCrossRefGoogle Scholar
  45. 45.
    Han EK, Gehrke L, Tahir SK, Credo RB, Cherian SP, Sham H, Rosenberg SH, Ng S (2000) Modulation of drug resistance by alpha-tubulin in paclitaxel-resistant human lung cancer cell lines. Eur J Cancer 36(12):1565–1571PubMedCrossRefGoogle Scholar
  46. 46.
    Kavallaris M, Burkhart CA, Horwitz SB (1999) Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol. Br J Cancer 80(7):1020–1025PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Zeng L, Kizaka-Kondoh S, Itasaka S, Xie X, Inoue M, Tanimoto K, Shibuya K, Hiraoka M (2007) Hypoxia inducible factor-1 influences sensitivity to paclitaxel of human lung cancer cell lines under normoxic conditions. Cancer Sci 98(9):1394–1401PubMedCrossRefGoogle Scholar
  48. 48.
    Goncalves A, Braguer D, Kamath K, Martello L, Briand C, Horwitz S, Wilson L, Jordan MA (2001) Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics. Proc Natl Acad Sci U S A 98(20):11737–11742PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Marcus AI, Zhou J, O’Brate A, Hamel E, Wong J, Nivens M, El-Naggar A, Yao TP, Khuri FR, Giannakakou P (2005) The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase. Cancer Res 65(9):3883–3893PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Dumontet C, Isaac S, Souquet PJ, Bejui-Thivolet F, Pacheco Y, Peloux N, Frankfurter A, Luduena R, Perol M (2005) Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer 92(2):E25–E30PubMedGoogle Scholar
  51. 51.
    Seve P, Mackey J, Isaac S, Tredan O, Souquet PJ, Perol M, Lai R, Voloch A, Dumontet C (2005) Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 4(12):2001–2007PubMedCrossRefGoogle Scholar
  52. 52.
    Monzo M, Rosell R, Sanchez JJ, Lee JS, O’Brate A, Gonzalez-Larriba JL, Alberola V, Lorenzo JC, Nunez L, Ro JY, Martin C (1999) Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 17(6):1786–1793PubMedCrossRefGoogle Scholar
  53. 53.
    Masuda A, Maeno K, Nakagawa T, Saito H, Takahashi T (2003) Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers. Am J Pathol 163(3):1109–1116. doi: 10.1016/S0002-9440(10)63470-0 PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Pommier Y, Leo E, Zhang H, Marchand C (2010) DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 17(5):421–433. doi: 10.1016/j.chembiol.2010.04.012 PubMedCrossRefGoogle Scholar
  55. 55.
    Kasahara K, Fujiwara Y, Sugimoto Y, Nishio K, Tamura T, Matsuda T, Saijo N (1992) Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines. J Natl Cancer Inst 84(2):113–118PubMedCrossRefGoogle Scholar
  56. 56.
    Tsujino I, Yamazaki T, Masutani M, Sawada U, Horie T (1999) Effect of Tween-80 on cell killing by etoposide in human lung adenocarcinoma cells. Cancer Chemother Pharmacol 43(1):29–34PubMedCrossRefGoogle Scholar
  57. 57.
    Belanger MM, Gaudreau M, Roussel E, Couet J (2004) Role of caveolin-1 in etoposide resistance development in A549 lung cancer cells. Cancer Biol Ther 3(10):954–959PubMedCrossRefGoogle Scholar
  58. 58.
    Yamazaki K, Isobe H, Hanada T, Betsuyaku T, Hasegawa A, Hizawa N, Ogura S, Kawakami Y (1997) Topoisomerase II alpha content and topoisomerase II catalytic activity cannot explain drug sensitivities to topoisomerase II inhibitors in lung cancer cell lines. Cancer Chemother Pharmacol 39(3):192–198PubMedCrossRefGoogle Scholar
  59. 59.
    Houlbrook S, Harris AL, Carmichael J, Stratford IJ (1996) Relationship between topoisomerase II levels and resistance to topoisomerase II inhibitors in lung cancer cell lines. Anticancer Res 16(4A):1603–1610PubMedGoogle Scholar
  60. 60.
    Andoh T, Nishizawa M, Hida T, Ariyoshi Y, Takahashi T, Ueda R (1996) Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection. Oncol Res 8(6):229–238PubMedGoogle Scholar
  61. 61.
    Guinee DG Jr, Holden JA, Benfield JR, Woodward ML, Przygodzki RM, Fishback NF, Koss MN, Travis WD (1996) Comparison of DNA topoisomerase II alpha expression in small cell and nonsmall cell carcinoma of the lung. In search of a mechanism of chemotherapeutic response. Cancer 78(4):729–735PubMedCrossRefGoogle Scholar
  62. 62.
    Kreisholt J, Sorensen M, Jensen PB, Nielsen BS, Andersen CB, Sehested M (1998) Immunohistochemical detection of DNA topoisomerase IIalpha, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer. Br J Cancer 77(9):1469–1473PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Hansen LT, Lundin C, Spang-Thomsen M, Petersen LN, Helleday T (2003) The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer. Int J Cancer 105(4):472–479PubMedCrossRefGoogle Scholar
  64. 64.
    Kraus AC, Ferber I, Bachmann SO, Specht H, Wimmel A, Gross MW, Schlegel J, Suske G, Schuermann M (2002) In vitro chemo- and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways. Oncogene 21(57):8683–8695PubMedCrossRefGoogle Scholar
  65. 65.
    Lee SM, Lee CT, Kim YW, Han SK, Shim YS, Yoo CG (2006) Hypoxia confers protection against apoptosis via PI3K/Akt and ERK pathways in lung cancer cells. Cancer Lett 242(2):231–238PubMedCrossRefGoogle Scholar
  66. 66.
    Shimoda R, Achanzar WE, Qu W, Nagamine T, Takagi H, Mori M, Waalkes MP (2003) Metallothionein is a potential negative regulator of apoptosis. Toxicol Sci 73(2):294–300PubMedCrossRefGoogle Scholar
  67. 67.
    Smith GC, Jackson SP (1999) The DNA-dependent protein kinase. Genes Dev 13(8):916–934PubMedCrossRefGoogle Scholar
  68. 68.
    Mini E, Nobili S, Caciagli B, Landini I, Mazzei T (2006) Cellular pharmacology of gemcitabine. Ann Oncol 17(Suppl 5):v7–v12. doi: 10.1093/annonc/mdj941 PubMedCrossRefGoogle Scholar
  69. 69.
    Seve P, Mackey JR, Isaac S, Tredan O, Souquet PJ, Perol M, Cass C, Dumontet C (2005) cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer. Lung Cancer 49(3):363–370PubMedCrossRefGoogle Scholar
  70. 70.
    Kim MJ, Lee HJ, Lee IA, Kim IY, Lim SK, Cho HA, Kim JS (2008) Preparation of pH-sensitive, long-circulating and EGFR-targeted immunoliposomes. Arch Pharm Res 31(4):539–546PubMedCrossRefGoogle Scholar
  71. 71.
    Oguri T, Achiwa H, Muramatsu H, Ozasa H, Sato S, Shimizu S, Yamazaki H, Eimoto T, Ueda R (2007) The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer. Cancer Lett 256(1):112–119PubMedCrossRefGoogle Scholar
  72. 72.
    Bepler G, Kusmartseva I, Sharma S, Gautam A, Cantor A, Sharma A, Simon G (2006) RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 24(29):4731–4737PubMedCrossRefGoogle Scholar
  73. 73.
    Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM, Slapak CA (2004) An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 64(11):3761–3766PubMedCrossRefGoogle Scholar
  74. 74.
    Kwon WS, Rha SY, Choi YH, Lee JO, Park KH, Jung JJ, Kim TS, Jeung HC, Chung HC (2006) Ribonucleotide reductase M1 (RRM1) 2464G > A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. Pharmacogenet Genomics 16(6):429–438PubMedCrossRefGoogle Scholar
  75. 75.
    Tooker P, Yen WC, Ng SC, Negro-Vilar A, Hermann TW (2007) Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification. Cancer Res 67(9):4425–4433PubMedCrossRefGoogle Scholar
  76. 76.
    Oguri T, Achiwa H, Sato S, Bessho Y, Takano Y, Miyazaki M, Muramatsu H, Maeda H, Niimi T, Ueda R (2006) The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity. Mol Cancer Ther 5(7):1800–1806PubMedCrossRefGoogle Scholar
  77. 77.
    Shimizu J, Horio Y, Osada H, Hida T, Hasegawa Y, Shimokata K, Takahashi T, Sekido Y, Yatabe Y (2008) mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines. Respirology 13(4):510–517PubMedCrossRefGoogle Scholar
  78. 78.
    Rosell R, Felip E, Taron M, Majo J, Mendez P, Sanchez-Ronco M, Queralt C, Sanchez JJ, Maestre J (2004) Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res 10(12 Pt 2):4215s–4219sPubMedCrossRefGoogle Scholar
  79. 79.
    Rosell R, Scagliotti G, Danenberg KD, Lord RV, Bepler G, Novello S, Cooc J, Crino L, Sanchez JJ, Taron M, Boni C, De Marinis F, Tonato M, Marangolo M, Gozzelino F, Di Costanzo F, Rinaldi M, Salonga D, Stephens C (2003) Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 22(23):3548–3553PubMedCrossRefGoogle Scholar
  80. 80.
    Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, Camps C, Provencio M, Isla D, Taron M, Diz P, Artal A (2004) Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 10(4):1318–1325PubMedCrossRefGoogle Scholar
  81. 81.
    Ceppi P, Volante M, Novello S, Rapa I, Danenberg KD, Danenberg PV, Cambieri A, Selvaggi G, Saviozzi S, Calogero R, Papotti M, Scagliotti GV (2006) ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 17(12):1818–1825PubMedCrossRefGoogle Scholar
  82. 82.
    Souglakos J, Boukovinas I, Taron M, Mendez P, Mavroudis D, Tripaki M, Hatzidaki D, Koutsopoulos A, Stathopoulos E, Georgoulias V, Rosell R (2008) Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. Br J Cancer 98(10):1710–1715PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Stuckler D, Singhal J, Singhal SS, Yadav S, Awasthi YC, Awasthi S (2005) RLIP76 transports vinorelbine and mediates drug resistance in non-small cell lung cancer. Cancer Res 65(3):991–998PubMedGoogle Scholar
  84. 84.
    Gregory RK, Smith IE (2000) Vinorelbine–a clinical review. Br J Cancer 82(12):1907–1913. doi: 10.1054/bjoc.2000.1203 PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Archambault V, Glover DM (2009) Polo-like kinases: conservation and divergence in their functions and regulation. Nat Rev Mol Cell Biol 10(4):265–275. doi: 10.1038/nrm2653, nrm2653 [pii]PubMedCrossRefGoogle Scholar
  86. 86.
    Zhou Q, Bai M, Su Y (2004) Effect of antisense RNA targeting polo-like kinase 1 on cell cycle and proliferation in A549 cells. Chin Med J (Engl) 117(11):1642–1649Google Scholar
  87. 87.
    Seve P, Isaac S, Tredan O, Souquet PJ, Pacheco Y, Perol M, Lafanechere L, Penet A, Peiller EL, Dumontet C (2005) Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 11(15):5481–5486PubMedCrossRefGoogle Scholar
  88. 88.
    Seve P, Lai R, Ding K, Winton T, Butts C, Mackey J, Dumontet C, Dabbagh L, Aviel-Ronen S, Seymour L, Whitehead M, Tsao MS, Shepherd FA, Reiman T (2007) Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res 13(3):994–999PubMedCrossRefGoogle Scholar
  89. 89.
    Nishio K, Nakamura T, Koh Y, Kanzawa F, Tamura T, Saijo N (2001) Oncoprotein 18 overexpression increases the sensitivity to vindesine in the human lung carcinoma cells. Cancer 91(8):1494–1499PubMedCrossRefGoogle Scholar
  90. 90.
    Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26(21):3543–3551PubMedCrossRefGoogle Scholar
  91. 91.
    Zhao R, Qiu A, Tsai E, Jansen M, Akabas MH, Goldman ID (2008) The proton-coupled folate transporter: impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier. Mol Pharmacol 74(3):854–862. doi: 10.1124/mol.108.045443, mol.108.045443 [pii]PubMedPubMedCentralCrossRefGoogle Scholar
  92. 92.
    Chattopadhyay S, Wang Y, Zhao R, Goldman ID (2004) Lack of impact of the loss of constitutive folate receptor alpha expression, achieved by RNA Interference, on the activity of the new generation antifolate pemetrexed in HeLa cells. Clin Cancer Res 10(23):7986–7993. doi: 10.1158/1078-0432.CCR-04-1225, 10/23/7986 [pii]PubMedCrossRefGoogle Scholar
  93. 93.
    Theti DS, Jackman AL (2004) The role of alpha-folate receptor-mediated transport in the antitumor activity of antifolate drugs. Clin Cancer Res 10(3):1080–1089PubMedCrossRefGoogle Scholar
  94. 94.
    Nunez MI, Behrens C, Woods DM, Lin H, Prudkin L, Suraokar M, Girard L, Minna JD, Lee JJ, Hofstetter W, Franklin W, Moran CA, Stewart DJ, Wistuba II (2009) Immunohistochemical expression of membrane transporters correlates with histology type of non-small cell lung carcinoma. In: Proceedings of the 100th annual meeting of the American Association of Cancer Research: Abstract #1594Google Scholar
  95. 95.
    Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Del Tacca M, Danesi R (2005) Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 68(1):110–118PubMedGoogle Scholar
  96. 96.
    Liu Y, Yin TJ, Zhou R, Zhou S, Fan L, Zhang RG (2013) Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis. Cancer Chemother Pharmacol 72(5):1125–1132. doi: 10.1007/s00280-013-2299-2 PubMedCrossRefGoogle Scholar
  97. 97.
    Chattopadhyay S, Tamari R, Min SH, Zhao R, Tsai E, Goldman ID (2007) Commentary: a case for minimizing folate supplementation in clinical regimens with pemetrexed based on the marked sensitivity of the drug to folate availability. Oncologist 12(7):808–815PubMedCrossRefGoogle Scholar
  98. 98.
    Stewart DJ (2010) Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol 75(3):173–234. doi: 10.1016/j.critrevonc.2009.11.006, S1040-8428(09)00230-3 [pii]PubMedPubMedCentralCrossRefGoogle Scholar
  99. 99.
    Stewart DJ, Tomiak E, Shamji FM, Maziak DE, MacLeod P (2004) Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer. Lung Cancer 44(2):241–249. doi: 10.1016/j.lungcan.2003.10.009, S0169500203005592 [pii]PubMedCrossRefGoogle Scholar
  100. 100.
    Giaccone G, van Ark-Otte J, Rubio GJ, Gazdar AF, Broxterman HJ, Dingemans AM, Flens MJ, Scheper RJ, Pinedo HM (1996) MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lungs. Int J Cancer 66(6):760–767PubMedCrossRefGoogle Scholar
  101. 101.
    Campling BG, Young LC, Baer KA, Lam YM, Deeley RG, Cole SP, Gerlach JH (1997) Expression of the MRP and MDR1 multidrug resistance genes in small cell lung cancer. Clin Cancer Res 3(1):115–122PubMedGoogle Scholar
  102. 102.
    Bessho Y, Oguri T, Ozasa H, Uemura T, Sakamoto H, Miyazaki M, Maeno K, Sato S, Ueda R (2009) ABCC10/MRP7 is associated with vinorelbine resistance in non-small cell lung cancer. Oncol Rep 21(1):263–268PubMedGoogle Scholar
  103. 103.
    Young LC, Campling BG, Cole SP, Deeley RG, Gerlach JH (2001) Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res 7(6):1798–1804PubMedGoogle Scholar
  104. 104.
    Narasaki F, Oka M, Fukuda M, Ikeda K, Terashi K, Takatani H, Nakamura T, Soda H, Kohno S (1997) Multidrug resistance-associated protein gene expression and drug sensitivity in human lung cancer cells. Anticancer Res 17(5A):3493–3497PubMedGoogle Scholar
  105. 105.
    Henness S, Davey MW, Harvie RM, Davey RA (2002) Fractionated irradiation of H69 small-cell lung cancer cells causes stable radiation and drug resistance with increased MRP1, MRP2, and topoisomerase IIalpha expression. Int J Radiat Oncol Biol Phys 54(3):895–902PubMedCrossRefGoogle Scholar
  106. 106.
    Oguri T, Ozasa H, Uemura T, Bessho Y, Miyazaki M, Maeno K, Maeda H, Sato S, Ueda R (2008) MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer. Mol Cancer Ther 7(5):1150–1155PubMedCrossRefGoogle Scholar
  107. 107.
    Gonzalez Manzano R, Versanvoort C, Wright K, Twentyman PR (1996) Rapid recovery of a functional MDR phenotype caused by MRP after a transient exposure to MDR drugs in a revertant human lung cancer cell line. Eur J Cancer 32A(12):2136–2141PubMedCrossRefGoogle Scholar
  108. 108.
    Zaman GJ, Lankelma J, van Tellingen O, Beijnen J, Dekker H, Paulusma C, Oude Elferink RP, Baas F, Borst P (1995) Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc Natl Acad Sci U S A 92(17):7690–7694PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Liang Y, O’Driscoll L, McDonnell S, Doolan P, Oglesby I, Duffy K, O’Connor R, Clynes M (2004) Enhanced in vitro invasiveness and drug resistance with altered gene expression patterns in a human lung carcinoma cell line after pulse selection with anticancer drugs. Int J Cancer 111(4):484–493PubMedCrossRefGoogle Scholar
  110. 110.
    Ikuta K, Takemura K, Sasaki K, Kihara M, Nishimura M, Ueda N, Naito S, Lee E, Shimizu E, Yamauchi A (2005) Expression of multidrug resistance proteins and accumulation of cisplatin in human non-small cell lung cancer cells. Biol Pharm Bull 28(4):707–712PubMedCrossRefGoogle Scholar
  111. 111.
    van Ark-Otte J, Samelis G, Rubio G, Lopez Saez JB, Pinedo HM, Giaccone G (1998) Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypes. Oncol Rep 5(1):249–255PubMedGoogle Scholar
  112. 112.
    Bergman AM, Pinedo HM, Talianidis I, Veerman G, Loves WJ, van der Wilt CL, Peters GJ (2003) Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br J Cancer 88(12):1963–1970PubMedPubMedCentralCrossRefGoogle Scholar
  113. 113.
    Xu M, Li J, Xia Q (1999) Expression of multidrug resistance-associated protein gene in non-small cell lung cancer. Zhonghua Jie He He Hu Xi Za Zhi 22(5):268–270PubMedGoogle Scholar
  114. 114.
    Oshika Y, Nakamura M, Tokunaga T, Fukushima Y, Abe Y, Ozeki Y, Yamazaki H, Tamaoki N, Ueyama Y (1998) Multidrug resistance-associated protein and mutant p53 protein expression in non-small cell lung cancer. Mod Pathol 11(11):1059–1063PubMedGoogle Scholar
  115. 115.
    Ota E, Abe Y, Oshika Y, Ozeki Y, Iwasaki M, Inoue H, Yamazaki H, Ueyama Y, Takagi K, Ogata T et al (1995) Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer. Br J Cancer 72(3):550–554PubMedPubMedCentralCrossRefGoogle Scholar
  116. 116.
    Triller N, Korosec P, Kern I, Kosnik M, Debeljak A (2006) Multidrug resistance in small cell lung cancer: expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease. Lung Cancer 54(2):235–240PubMedCrossRefGoogle Scholar
  117. 117.
    Yeh JJ, Hsu NY, Hsu WH, Tsai CH, Lin CC, Liang JA (2005) Comparison of chemotherapy response with P-glycoprotein, multidrug resistance-related protein-1, and lung resistance-related protein expression in untreated small cell lung cancer. Lung 183(3):177–183PubMedCrossRefGoogle Scholar
  118. 118.
    Ushijima R, Takayama K, Izumi M, Harada T, Horiuchi Y, Uchino J, Hara N, Nakanishi Y (2007) Immunohistochemical expression of MRP2 and clinical resistance to platinum-based chemotherapy in small cell lung cancer. Anticancer Res 27(6C):4351–4358PubMedGoogle Scholar
  119. 119.
    Oguri T, Isobe T, Fujitaka K, Ishikawa N, Kohno N (2001) Association between expression of the MRP3 gene and exposure to platinum drugs in lung cancer. Int J Cancer 93(4):584–589PubMedCrossRefGoogle Scholar
  120. 120.
    Oguri T, Isobe T, Suzuki T, Nishio K, Fujiwara Y, Katoh O, Yamakido M (2000) Increased expression of the MRP5 gene is associated with exposure to platinum drugs in lung cancer. Int J Cancer 86(1):95–100PubMedCrossRefGoogle Scholar
  121. 121.
    Han JY, Lim HS, Yoo YK, Shin ES, Park YH, Lee SY, Lee JE, Lee DH, Kim HT, Lee JS (2007) Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 110(1):138–147PubMedCrossRefGoogle Scholar
  122. 122.
    Dingemans AC, van Ark-Otte J, Span S, Scagliotti GV, van der Valk P, Postmus PE, Giaccone G (2001) Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer. Lung Cancer 32(2):117–128PubMedCrossRefGoogle Scholar
  123. 123.
    Wang J, Liu X, Jiang W (2000) Expression of LRP, MRP and MDR1 in non-small-cell lung cancer and its clinical significance. Zhonghua Zhong Liu Za Zhi 22(4):304–307PubMedGoogle Scholar
  124. 124.
    Filipits M, Haddad V, Schmid K, Huynh A, Dunant A, Andre F, Brambilla E, Stahel R, Pignon JP, Soria JC, Popper HH, Le Chevalier T, Pirker R (2007) Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program. Clin Cancer Res 13(13):3892–3898PubMedCrossRefGoogle Scholar
  125. 125.
    NicAmhlaoibh R, Heenan M, Cleary I, Touhey S, O’Loughlin C, Daly C, Nunez G, Scanlon KJ, Clynes M (1999) Altered expression of mRNAs for apoptosis-modulating proteins in a low level multidrug resistant variant of a human lung carcinoma cell line that also expresses mdr1 mRNA. Int J Cancer 82(3):368–376PubMedCrossRefGoogle Scholar
  126. 126.
    Yabuki N, Sakata K, Yamasaki T, Terashima H, Mio T, Miyazaki Y, Fujii T, Kitada K (2007) Gene amplification and expression in lung cancer cells with acquired paclitaxel resistance. Cancer Genet Cytogenet 173(1):1–9PubMedCrossRefGoogle Scholar
  127. 127.
    Pesic M, Markovic JZ, Jankovic D, Kanazir S, Markovic ID, Rakic L, Ruzdijic S (2006) Induced resistance in the human non small cell lung carcinoma (NCI-H460) cell line in vitro by anticancer drugs. J Chemother 18(1):66–73PubMedCrossRefGoogle Scholar
  128. 128.
    Sato H, Fukumoto K, Hada S, Hagiwara H, Fujimoto E, Negishi E, Ueno K, Yano T (2007) Enhancing effect of connexin 32 gene on vinorelbine-induced cytotoxicity in A549 lung adenocarcinoma cells. Cancer Chemother Pharmacol 60(3):449–457PubMedCrossRefGoogle Scholar
  129. 129.
    Ji D, Deeds SL, Weinstein EJ (2007) A screen of shRNAs targeting tumor suppressor genes to identify factors involved in A549 paclitaxel sensitivity. Oncol Rep 18(6):1499–1505PubMedGoogle Scholar
  130. 130.
    Kitazaki T, Oka M, Nakamura Y, Tsurutani J, Doi S, Yasunaga M, Takemura M, Yabuuchi H, Soda H, Kohno S (2005) Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer 49(3):337–343PubMedCrossRefGoogle Scholar
  131. 131.
    Glisson BS, Alpeter MD (1992) Multidrug resistance in a small cell lung cancer line: rapid selection with etoposide and differential chemosensitization with cyclosporin A. Anticancer Drugs 3(4):359–366PubMedCrossRefGoogle Scholar
  132. 132.
    Takigawa N, Ohnoshi T, Ueoka H, Kiura K, Kimura I (1992) Establishment and characterization of an etoposide-resistant human small cell lung cancer cell line. Acta Med Okayama 46(3):203–212PubMedGoogle Scholar
  133. 133.
    Xia S, Yu SY, Yuan XL, Xu SP (2004) Effects of hypoxia on expression of P-glycoprotein and multidrug resistance protein in human lung adenocarcinoma A549 cell line. Zhonghua Yi Xue Za Zhi 84(8):663–666PubMedGoogle Scholar
  134. 134.
    Yasuda H, Nakayama K, Watanabe M, Suzuki S, Fuji H, Okinaga S, Kanda A, Zayasu K, Sasaki T, Asada M, Suzuki T, Yoshida M, Yamanda S, Inoue D, Kaneta T, Kondo T, Takai Y, Sasaki H, Yanagihara K, Yamaya M (2006) Nitroglycerin treatment may enhance chemosensitivity to docetaxel and carboplatin in patients with lung adenocarcinoma. Clin Cancer Res 12(22):6748–6757PubMedCrossRefGoogle Scholar
  135. 135.
    Oka M, Fukuda M, Sakamoto A, Takatani H, Fukuda M, Soda H, Kohno S (1997) The clinical role of MDR1 gene expression in human lung cancer. Anticancer Res 17(1B):721–724PubMedGoogle Scholar
  136. 136.
    Inoue Y, Gika M, Abiko T, Oyama T, Saitoh Y, Yamazaki H, Nakamura M, Abe Y, Kawamura M, Kobayashi K (2005) Bcl-2 overexpression enhances in vitro sensitivity against docetaxel in non-small cell lung cancer. Oncol Rep 13(2):259–264PubMedGoogle Scholar
  137. 137.
    Peng ZM, Luo J, Wang WB, Wang XH, Chen JH, Lan SM (2004) Predictive value of drug resistance-related genes expression in neoadjuvant chemotherapy in patients with non-small cell lung cancer of stage III. Ai Zheng 23(8):963–967PubMedGoogle Scholar
  138. 138.
    Kawasaki M, Nakanishi Y, Kuwano K, Takayama K, Kiyohara C, Hara N (1998) Immunohistochemically detected p53 and P-glycoprotein predict the response to chemotherapy in lung cancer. Eur J Cancer 34(9):1352–1357PubMedCrossRefGoogle Scholar
  139. 139.
    Kao A, Shiun SC, Hsu NY, Sun SS, Lee CC, Lin CC (2001) Technetium-99m methoxyisobutylisonitrile chest imaging for small-cell lung cancer. Relationship to chemotherapy response (six courses of combination of cisplatin and etoposide) and p-glycoprotein or multidrug resistance related protein expression. Ann Oncol 12(11):1561–1566PubMedCrossRefGoogle Scholar
  140. 140.
    Yeh JJ, Hsu WH, Huang WT, Wang JJ, Ho ST, Kao A (2003) Technetium-99m tetrofosmin SPECT predicts chemotherapy response in small cell lung cancer. Tumour Biol 24(3):151–155PubMedCrossRefGoogle Scholar
  141. 141.
    Savaraj N, Wu CJ, Xu R, Lampidis T, Lai S, Donnelly E, Solomon J, Feun LG (1997) Multidrug-resistant gene expression in small-cell lung cancer. Am J Clin Oncol 20(4):398–403PubMedCrossRefGoogle Scholar
  142. 142.
    Sohn JW, Lee SY, Lee SJ, Kim EJ, Cha SI, Kim CH, Lee JT, Jung TH, Park JY (2006) MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer. Jpn J Clin Oncol 36(3):137–141PubMedCrossRefGoogle Scholar
  143. 143.
    Hsu WH, Yen RF, Kao CH, Shiun SC, Hsu NY, Lin CC, Lee CC (2002) Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer (stage IIIb or IV) with a higher T stage (>T2). Technetium-99m methoxyisobutylisonitrile chest single photon emission computed tomography and P-glycoprotein express ion. Oncology 63(2):173–179PubMedCrossRefGoogle Scholar
  144. 144.
    Yeh JJ, Hsu WH, Wang JJ, Ho ST, Kao A (2003) Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer with P-glycoprotein expression. Respiration 70(1):32–35PubMedCrossRefGoogle Scholar
  145. 145.
    Pan JH, Han JX, Wu JM, Sheng LJ, Huang HN, Yu QZ (2008) MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer. Respiration 75(4):380–385PubMedCrossRefGoogle Scholar
  146. 146.
    Miyatake K, Gemba K, Ueoka H, Nishii K, Kiura K, Tabata M, Shibayama T, Takigawa N, Kawaraya M, Tanimoto M (2003) Prognostic significance of mutant p53 protein, P-glycoprotein and glutathione S-transferase-pi in patients with unresectable non-small cell lung cancer. Anticancer Res 23(3C):2829–2836PubMedGoogle Scholar
  147. 147.
    Brooks KR, To K, Joshi MB, Conlon DH, Herndon JE 2nd, D’Amico TA, Harpole DH Jr (2003) Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection. Ann Thorac Surg 76(1):187–193, discussion 193PubMedCrossRefGoogle Scholar
  148. 148.
    Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M, Lopez-Vivanco G, Camps C, Botia M, Nunez L, Sanchez-Ronco M, Sanchez JJ, Lopez-Brea M, Barneto I, Paredes A, Medina B, Artal A, Lianes P (2004) Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 15(8):1194–1203PubMedCrossRefGoogle Scholar
  149. 149.
    Yang CH, Huang CJ, Yang CS, Chu YC, Cheng AL, Whang-Peng J, Yang PC (2005) Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. Cancer Res 65(15):6943–6949PubMedCrossRefGoogle Scholar
  150. 150.
    Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 1. J Clin Oncol 22(5):777–784PubMedCrossRefGoogle Scholar
  151. 151.
    Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 2. J Clin Oncol 22(5):785–794PubMedCrossRefGoogle Scholar
  152. 152.
    Kruijtzer CM, Schellens JH, Mezger J, Scheulen ME, Keilholz U, Beijnen JH, Rosing H, Mathot RA, Marcus S, van Tinteren H, Baas P (2002) Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer. J Clin Oncol 20(23):4508–4516PubMedCrossRefGoogle Scholar
  153. 153.
    Ross HJ, Cho J, Osann K, Wong SF, Ramsinghani N, Williams J, Downey-Hurtado N, Slater LM (1997) Phase I/II trial of low dose cyclosporin A with EP for advanced non-small cell lung cancer. Lung Cancer 18(2):189–198, S0169-5002(97)00061-5[pii]PubMedCrossRefGoogle Scholar
  154. 154.
    Christen RD, Shalinsky DR, Howell SB (1992) Enhancement of the loss of multiple drug resistance by hydroxyurea. Semin Oncol 19(3 Suppl 9):94–100PubMedGoogle Scholar
  155. 155.
    Stewart DJ, Tomiak EM, Goss G, Gertler SZ, Logan D, Huan S, Yau J, Dulude H, Evans WK (1996) Paclitaxel plus hydroxyurea as second line therapy for non-small cell lung cancer. Lung Cancer 15(1):115–123, 0169500296005764 [pii]PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Department of Medicine, James P. Wilmot Cancer CenterUniversity of RochesterRochesterUSA

Personalised recommendations